Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • High levels of global hydroxym...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
High levels of global hydroxymethylation predict worse overall survival in MDS patients treated with azacitidine

High levels of global hydroxymethylation predict worse overall survival in MDS patients treated with azacitidine

Bibliographic Details
Main Authors: Francesca Tiso, Florentien E. M. in 't Hout, Ruth Knops, Leonie I. Kroeze, Arno vanRooij, Arjan A. van deLoosdrecht, Theresia M. Westers, Saskia M. C. Langemeijer, Claude Preudhomme, Nicolas Duployez, Pierre Fenaux, Olivier Kosmider, Didier Bouscary, Aniek O. deGraaf, Joost H. A. Martens, Bert A. van derReijden, Lionel Adès, Michaela Fontenay, Joop H. Jansen
Format: Article
Language:English
Published: Wiley 2025-01-01
Series:HemaSphere
Online Access:https://doi.org/10.1002/hem3.70034
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

https://doi.org/10.1002/hem3.70034

Similar Items

  • Somatic mutations and DNA methylation identify a subgroup of poor prognosis within lower‐risk myelodysplastic syndromes
    by: David Rombaut, et al.
    Published: (2025-01-01)
  • Very long-term remission with azacitidine in VEXAS syndrome
    by: Lin-Pierre Zhao, et al.
    Published: (2025-01-01)
  • High expression of transcription factor 4 (TCF4) is an independent adverse prognostic factor in acute myeloid leukemia that could guide treatment decisions
    by: Florentien E.M. in ’t Hout, et al.
    Published: (2014-12-01)
  • P455: RUNX1 DIRECTLY BINDS AND REGULATES THE TCF4 PROMOTER
    by: Mylene Gerritsen, et al.
    Published: (2023-08-01)
  • Expression levels of genes implicated in the working mechanism of lenalidomide predict treatment response in lower risk myelodysplastic syndrome patients
    by: Florentien E.M. in’t Hout, et al.
    Published: (2024-10-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs